Published in Lab Business Week, April 9th, 2006
The outlook for the market is currently strong, driven by strategically sound lifecycle management from the major players in the asthma and chronic obstructive pulmonary disease (COPD) area, new product launches and favorable epidemiology. Generic competition will continue to remain the major threat to sales growth in this market, according to the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.